Department of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, 28040, Spain.
Institute of Industrial Pharmacy, Complutense University of Madrid, Madrid, 28040, Spain.
Br J Pharmacol. 2018 Jul;175(13):2566-2580. doi: 10.1111/bph.14331. Epub 2018 May 22.
In the last few decades, the endocannabinoid system has attracted a great deal of interest in terms of its applications to clinical medicine. In particular, its applications in cancer probably represent one of the therapeutic areas with most promise. On the one hand, expression of the endocannabinoid system is altered in numerous types of tumours, compared to healthy tissue, and this aberrant expression has been related to cancer prognosis and disease outcome, suggesting a role of this system in tumour growth and progression that depends on cancer type. On the other hand, cannabinoids exert an anticancer activity by inhibiting the proliferation, migration and/or invasion of cancer cells and also tumour angiogenesis. However, some cannabinoids, at lower concentrations, may increase tumour proliferation, inducing cancer growth. Enough data has been provided to consider the endocannabinoid system as a new therapeutic target in cancer, although further studies to fully establish the effect of cannabinoids on tumour progression are still needed.
在过去几十年中，内源性大麻素系统因其在临床医学中的应用而引起了极大的关注。特别是，它在癌症中的应用可能代表了最有前途的治疗领域之一。一方面，与健康组织相比，内源性大麻素系统在许多类型的肿瘤中表达发生改变，这种异常表达与癌症预后和疾病结局相关，表明该系统在肿瘤生长和进展中发挥作用，其作用取决于癌症类型。另一方面，大麻素通过抑制癌细胞的增殖、迁移和/或侵袭以及肿瘤血管生成来发挥抗癌作用。然而，一些大麻素在较低浓度下可能会增加肿瘤增殖，从而促进癌症生长。已经提供了足够的数据来将内源性大麻素系统视为癌症的一个新的治疗靶点，尽管仍需要进一步的研究来充分确定大麻素对肿瘤进展的影响。
